On Monday, Oi S.A. (NYSE:OIBR)’s shares surged 2.46% to $2.08, as on April 1, Oi following art. 157, paragraph 4, of Law No. 6,404/76 and Instruction No. 358/02 of the Brazilian Securities and Exchange Commission (Comissao de Valores Mobiliarios – CVM), and in furtherance with the Material Fact published on March 26, 2015, informed its shareholders and the market in general, that on this date, Telemar Participacoes S.A. revealed the following Material Fact.
“Telemar Participacoes S.A., following art. 157, paragraph 4, of Law No. 6,404/76 and Instruction No. 358/02 of the Brazilian Securities and Exchange Commission (Comissao de Valores Mobiliarios – CVM), and in furtherance of the Material Fact published on March 26, 2015, informs that, in the shareholders’ meeting planned for March 31, 2015, in accordance with the terms of TmarPart’s Shareholders’ Contract, the administration of TmarPart and Oi, respectively, received the approval to start taking the applicable steps to adopt a set of measures to meet the main aims of the planned business combination of Oi, TmarPart, and Portugal Telecom, SGPS, S.A., as published on February 20, 2014.
Oi S.A., through its auxiliaries, provides integrated telecommunication services for residential customers, companies, and governmental agencies in Brazil.
Pilgrim’s Pride Corporation (NASDAQ:PPC)’s shares gained 2.36% to $23.84, during the last trading session on Monday, as Pilgrim’s Pride will host its first quarter 2015 earnings conference call and webcast on Thursday, April 30, 2015 at 7:00 a.m. MDT (9:00 a.m. EDT). Prepared remarks regarding the company’s financial and operational results will be followed by a question and answer period with Pilgrim’s executive administration team.
Pilgrim’s Pride Corporation engages in the production, processing, marketing, and distribution of fresh, frozen, and value-added chicken products to retailers, distributors, and foodservice operators in the United States, Mexico, and Puerto Rico. It offers fresh chicken products comprising pre-marinated or non-marinated, and prepackaged refrigerated (nonfrozen) whole or cut-up chicken in various combinations of refrigerated whole chickens and chicken parts.
At the end of Monday’s trade, Williams Partners L.P. (NYSE:WPZ)’s shares gained 2.22% to $49.66, as on April 6, Energy Partners, L.P. (EVEP) declared that it has signed a definitive contract to divest its entire 21 percent interest in Utica East Ohio Midstream LLC (UEO), to Utica Gas Services, L.L.C., a partner of Williams Partners L.P. (WPZ), for total cash consideration of $575 million. EVEP’s net capital contribution to UEO has been about $294 million. The contract is subject to customary purchase price adjustments and closing conditions, counting termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
The other member of UEO has the right to agree to attain EVEP’s interest in UEO for the same price. If the other member exercises and closes on this right, the aggregate purchase price received by EVEP would remain the same, and WPZ would attain an approximate 13 percent interest and the other member would attain an approximate 8 percent interest.
Jefferies LLC acted as EVEP’s exclusive financial advisor in connection with the pending divestiture.
Williams Partners L.P., an energy infrastructure company, focuses on connecting North America’s hydrocarbon resource plays to growing markets for natural gas and natural gas liquids (NGL). It operates in Northeast G&P, Atlantic-Gulf, West, and NGL & Petchem Services segments.
EV Energy Partners, L.P. is a master limited partnership engaged in acquiring, producing and developing oil and natural gas properties.
Finally, Seattle Genetics, Inc. (NASDAQ:SGEN), ended its Monday’s trading session with 2.18% gain, and closed at $37.90, after a biotechnology company, declared that it will report its first quarter 2015 financial results on Thursday, April 30 after the close of financial markets. Following the declaration, company administration will host a conference call and webcast discussion of the results and provide a general corporate update.
Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
